Vericel Stock

Vericel EBITDA per Employee

The EBITDA per Employee of Vericel (VCEL) as of Aug 21, 2026 is 45,825.73 USD. In the previous year, EBITDA per Employee was 18,751.04 USD — a change of 144.39% (higher).

EBITDA per Employee

45,825.73USD

YoY

144.39%

Last updated:

EBITDA per Employee of Vericel is 2026 45,825.73 USD. EBITDA per Employee of Vericel was 2025 18,751.04 USD. It decreases by 144.39% higher compared to the previous year.
Access this data via the Eulerpool API

Vericel Stock analysis

What does Vericel do? Vericel Corp is a US biotechnology company specializing in the development and commercialization of innovative cell therapies for patients with serious diseases. The company is headquartered in Cambridge, Massachusetts and was founded in 1997. Vericel is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vericel stock

EBITDA per Employee of Vericel is 45,825.73 USD in 2026.

EBITDA per Employee of Vericel changed from 18,751.04 USD to 45,825.73 USD, representing a 144.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Vericel since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Vericel historically and in real time.

Access this data via the Eulerpool API

Workforce — Vericel

All Key Metrics — Vericel